恩替卡韦联合阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎患者的疗效观察

鲍军; 梁军才; 龚力; 陈晓笑

doi:10.3969/j.issn.1001-5256.2014.10.014

恩替卡韦联合阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎患者的疗效观察

DOI: 10.3969/j.issn.1001-5256.2014.10.014

江苏省老年医院消化科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3598
- HTML全文浏览量: 15
- PDF下载量: 611
- 被引次数: 0
出版历程
- 收稿日期: 2014-07-28
- 出版日期: 2014-10-20

Clinical efficacy of combined treatment with entecavir and adefovir dipivoxil for lamivudine-resistant chronic hepatitis B

Department of Gastroenterology, Jiangsu Province Geriatric Hospital

摘要

摘要:
目的观察恩替卡韦联合阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎(CHB)患者的疗效和安全性。方法选取昆山市人民医院2011年5月至2013年5月门诊和住院的拉米夫定耐药患者45例,随机分成两组,治疗组23例应用恩替卡韦联合阿德福韦酯挽救治疗,对照组22例应用拉米夫定联合阿德福韦酯挽救治疗,观察两组治疗前及治疗后4、12、24、48周HBV DNA、ALT、AST、TBil、Alb、HBV血清学标志物含量变化以及治疗48周时非rtM204I位点变异发生率。计量资料组间比较用t检验,计数资料的组间比较用四格表χ2检验。结果治疗组挽救治疗后4、12周ALT、AST下降较对照组相比差异有统计学意义(t值为3.124、5.271、4.476、5.125,P值均<0.01),挽救治疗24、48周后较对照组相比差异有统计学意义(t值为2.240、2.307、2.886、2.908,P值均<0.05)。治疗4、12、24、48周后,治疗组HBV DNA转阴率分别为73.9%、86.8%、95.7%、100%,较对照组差异有统计学意义(χ2值为11.79、5.75、10.29、5.89,P值均&...
- 肝炎,乙型,慢性 /
- 恩替卡韦 /
- 阿德福韦酯 /
- 拉米夫定 /
- 联和治疗 /
- 耐药
Abstract:
Objective To evaluate the efficacy and safety of the combined therapy with entecavir ( ETV) and adefovir dipivoxil ( ADV) in patients with lamivudine ( LAM) -resistant chronic hepatitis B ( CHB) . Methods A total of 45 patients who were diagnosed with LAM-resistant CHB and admitted to the Kunshan People's Hospital from May 2011 to May 2013 were recruited in this study and randomly divided to two groups. The treatment group included 23 CHB patients who received the combined therapy with ETV and ADV. The control group included 22 CHB patients who received the combined therapy with LAM and ADV. The changes in levels of HBV DNA, alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , total bilirubin ( TBil) , albumin ( Alb) , and HBV serum markers before and after 4, 12, 24, and 48 weeks of treatment, as well as the rate of mutations other than that at rtM204 I after 48 weeks of treatment, were measured in both groups. Comparison of continuous data between groups was made by t test, and comparison of categorical data by fourfold table chi-square test. Results The levels of ALT and AST in the treatment group were significantly lower than those in the control group after 4 and 12 weeks of treatment ( t = 3. 124, 5. 271, 4. 476, 5. 125, all P < 0. 01) , as well as 24 and 48 weeks of treatment ( t = 2. 240, 2. 307, 2. 886, 2. 908, all P < 0. 05) . The serum HBV DNA clearance rates in the treatment group after 4, 12, 24, and 48 weeks of treatment were73. 9%, 86. 8%, 95. 7%, and 100%, respectively, all of which were significantly higher than those in the control group ( χ2= 11. 79, 5. 75, 10. 29, 5. 89, respectively, all P < 0. 05) . However, there was no significant difference in the HBeAg seroconversion rate among HBeAg-positive patients between the two groups. No mutations other than that at rtM204 I were found in the treatment group, while four new mutations were detected in the control group ( χ2= 4. 59, P < 0. 05) . Conclusion The combined therapy with ETV and ADV has good therapeutic effect in treating LAM-resistant CHB patients, and the clinical application is highly recommended.
- hepatitis B, chronic /
- ETV /
- ADV /
- LAM /
- combination therapy /
- drug resistance

HTML全文

参考文献(17)

[1]GANEM D, PRINCE AM.Hepatitis B virus infection--natural history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[2]ZHANG XH, LI ZP.Changes in serum complement components after 48 weeks of entecavir treatment in hepatitis B cirrhosis patients[J].J Clin Hepatol, 2013, 29 (5) :508-511. (in Chinese) 张雪华, 李仲平.恩替卡韦治疗乙型肝炎肝硬化患者48周前后血清补体的变化[J].临床肝胆病杂志, 2013, 29 (5) :508-511.

[3]LEUNG NW, LAI CL, CHANG TT, et al.Extended lamivudine treatment in patients with chronic hepatitis B enchances hepatitis B e antigen seroconversion rates:results after three years of therapy[J].Hepatology, 2001, 33 (6) :1527-1532.

[4]LAI CL, GANE E, LIAW YF, et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) :2576-2588.

[5]CHANG TT, GISH RG, de MAN R, et al.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2006, 354 (10) :1001-1010.

[6]LIM YS, HAN S, HEO NY, et al.Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine[J].Gastroenterology, 2014, 147 (1) :152-161.

[7]ZOULIM F, LOCARNINI S.Management of treatment failure in chronic hepatitis B[J].J Hepatol, 2012, 56:s112-s122.

[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[9]LAMPERTICO P, VIGANM, MANENTI E, et al.Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterology, 2007, 133 (5) :1445-1451.

[10]RYU HJ, LEE JM, AHN SH, et al.Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B[J].J Med Virol, 2010, 82 (11) :1843-1849.

[11]LEE YB, LEE JH, CHOI WM, et al.Efficacy of adefovir-based combination therapy for patients with lamivudine-and entecavir-resistant chronic hepatitis B virus infection[J].Antimicrob Agents Chemother, 2013, 57 (12) :6325-6332.

[12] LEE YS, SUH DJ, LIM YS, et al.Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after48 weeks of adefovir dipivoxil monotherapy[J].Hepatology, 2006, 43 (6) :1385-1391.

[13]SUZUKI Y, SUZUKI F, KAWAMURA Y, et al.Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years:Histological improvement or entecavir resistance[J].J Gastroenterol Hepatol, 2009, 24 (3) :429-435.

[14]CHO SW, KOH KH, CHEONG JY, et al.Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance[J].J Viral Hepat, 2010, 17 (3) :171-177.

[15]DELANEY WE 4th, YANG H, MILLER MD, et al.Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro[J].Antimicrob Agents Chemother, 2004, 48 (10) :3702-3710.

[16]ZENG T, XU H, LIU JY, et al.Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B:a meta-analysis[J].J Clin Pharmacol, 2014, 54 (9) :959-967.

[17]KE W, LIU L, ZHANG C, et al.Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection:a systematic review and meta-analysis[J].PLoS One, 2014, 9 (6) :e98476.

施引文献

资源附件(0)

访问统计